Inspiring the Future of Science to Deliver a Better Tomorrow

April 7, 2023

Lab technician working in a sterile laboratory.

ProPharma’s Research Consulting Organization (RCO) model offers a fully customizable alternative for partnership with clients and sponsors.

This year’s theme for World Health Day Health For All addresses the need to make healthcare more accessible for everyone. The National Institute of Health has reported that, while African Americans and Latinos make up 30% of the U.S. population, they account for less than 10% of participants in genetic studies. Practices used to recruit and involve research participants often fail to consider the diverse needs of different groups.

The pursuit of speed and responsibility in the development and commercialization of health solutions has been an ongoing challenge. The mantra "faster, better, cheaper" has echoed through the industry since the 1990s and Clinical Research Organizations (CROs) have stepped up to the plate to answer this call. Yet, while they have been successful in fitting themselves operationally to support the industry's ambitions, they have also created rigidity that means too many groups are left without support that fits their unique health needs.

A customized solution that combines traditional services with functional expertise and peer-to-peer collaboration, could lead to better patient outcomes by increasing diversity and the number of products reaching the market.

ProPharma, the world's largest Research Consulting Organization (RCO), this World Health Day has released a video in partnership with Reuters, demonstrating the value of their unique model in improving global health outcomes. ProPharma offers unparalleled drug development and medical device consulting expertise across the entire device development lifecycle. Unlike traditional CROs, ProPharma's RCO model prioritizes tailored solutions that maximize the probability of success and reduce the risk for clients.

ProPharma's global team of over 2,500 professionals spanning across six continents, is uniquely positioned to provide critical support services to pharmaceutical, biotechnology, and medical device clients worldwide. The company focuses on bringing novel therapies to market quickly and safely, underscoring its commitment to advancing improving patient outcomes and advancing health for all.

The company has built a bespoke, fit-for-purpose, and flexible solution with the resources each sponsor needs at any point in their development continuum. The innovative RCO model provides deep scientific and technical expertise, ensuring sponsors are supported and expertly advised by Subject Matter Experts (SMEs) to meet all the nuances of the process and maximize their chances of success. Furthermore, the company's regulatory sciences service line encompasses deep regional expertise, superior knowledge, and executive leadership backed up by the tactical know-how to structure complicated trials and deliver results.

This enables the customized design and delivery of consulting solutions equipped to navigate the increasingly complex global regulatory environment successfully. The RCO model is a game-changer for the world of life sciences, and ProPharma is at the forefront of this revolution.

Watch the Documentary




Array of different icons

March 11, 2024

How Important is Biostatistics?

The link between statistical methods and healthcare is not a new one, but the volume of available data to inform healthcare decisions and the use of data science in the medical industry has exploded...

August 8, 2022

Early engagement with Health Technology Assessment authorities will accelerate product launch and improve chances for reimbursement

Pharmaceutical companies should understand EU Health Technology Assessment (HTA) authorities requirements early in the product development phase. Engagement with HTA authorities during clinical...

September 12, 2016

FDA Updates Requirements Regarding Health Document Submissions for Tobacco Products

On Friday, September 9th, FDA announced the availability of a revised draft guidance, entitled “Health Document Submission Requirements for Tobacco Products.” The document was initially published in...